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Patients (or Materials) and Methods: Male Wistar rats were used 
(340 ± 20 g) at standard conditions. Hypertension was induced by 
a previously described surgical method (PAGE), which was obtained 
with measurements HAS stable (plethysmographic method) from 
the seventh postoperative day, the eighth day began therapy OHB, 
for 5 days per week for 4 weeks. At the end of treatment, the 
rats were sacrificed getting heart; this was mounted on a system 
of isolated organ (Langendorff system), and it was stimulating to 
logarithmic doses of angiotensin II (Ang II) to measure variations in 
vascular reactivity associated with the RAS in coronary resistance 
arteries. The results are analized with 2 way ANOVA and post hoc 
Von Ferroni.
Results: The diastolic pressure measurement was obtained a pressure 
of 150 ± 15 mm Hg, consistent with the definition of hypertension. 
When analyzing perfusion pressure resistance in coronary arteries, 
the HBP group without treatment showed an increase in vascular 
reactivity compared with the healthy group. Whereas the HBP with 
HBO group no presented changes in vascular reactivity to any dose 
of Ang II, compared with healthy control group.
Conclusion: HBO therapy reduces vascular reactivity in coronary 
resistance arteries under Ang II stimulation in a model of hyperten-
sion of renal origin. This suggests that HBO could be used with 
hypertensive patients to reduce the development of heart disease and 
in another way it could help to improve the functionality of the heart 
and reduce the use of drugs in the HBP treatment.
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Introduction: Augmented pervasiveness of type 2 diabetes mellitus 
and obesity has amplified the medical necessitate for new agents to 
treat these disease states. Both type 2 diabetes and obesity are con-
nected to the resistance to the hormones insulin and leptin. Protein 
tyrosine phosphatase 1B (PTP1B) has been shown to function as 
negative regulator of insulin signaling as well as leptin signal trans-
duction. This research exertion shows the molecular docking analysis 
of novel synthetically prepared compounds and new-fangled isolated 
natural PTP 1B inhibitors as novel target for type 2 diabetes.
Patients (or Materials) and Methods: Molegro Virtual Docker 
(MVD) has been used to dock novel natural PTP1B inhibitors with 
the Discovery Studio 3.0 visualizer.
Results: Molecular docking of novel natural PTP1B inhibitors 
showed some compounds with excellent dock score with greater 
binding affinity exhibiting pi-pi interactions
Conclusion: The plausible mechanism of action of various natural 
PTP1B inhibitors has been explained supported by in vitro experi-
mentation data. Traditional drugs with unknown mechanism of 
action were experimented for the PTP1B inhibitory activity and 
therefore are attention-grabbing biologically lead compounds.
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Introduction: Cardiac arrhythmia is 1 of the critical health condi-
tions. Clofibrate is a peroxisome proliferated-activator receptor-α 
(PPAR-α ) agonist that is widely used for reducing triglycerides in 
hyperlipidemic patients. Because this drug has showed several ben-
eficial effects in relief of some cardiovascular diseases, the aim of the 
present study was to evaluate antiarrhythmic effects of clofibrate on 
ouabain-induced arrhythmia in rats.
Patients (or Materials) and Methods: Twenty male rats weighing 
220 to 250 g were divided into 2 equal groups randomly. Group 1 
(treatment) received clofibrate (300 mg/kg) solved in olive oil (1 mL/
kg) once daily for 14 days intraperitoneally. Group 2 (vehicle control) 
only received olive oil (1 mL/kg) once daily for 14 days intraperito-
neally. After induction of anesthesia, heart was rapidly removed and 
the atria were immersed in a tissue bath containing modified Krebs 
solution andattached to isometric force transducer of PowerLab 
machine. Time of onset of arrhythmia and asystole, atrial beating 
rate, and contractile force were recorded and analyzed statistically 
with paired and Student’s t test in treatment and control groups.
Results: Clofibrate significantly postponed time of onset of arrhyth-
mia (23.57 [4.69] minutes) rather than control group (2.04 [0.27] 
minutes; P = 0.024). A significant increase in the onset time of asys-
tole in treatment group (66.19 [12.33] minutes) was observed, while 
this time for control group was 22.77 (7.17) (P = 0.004). Incubation 
of ouabain increased the atrial beating rate in control group signifi-
cantly (P = 0.022), while it does not show such effect in treatment 
group (P = 0.845). Incubation of ouabain had no effects on con-
tractile force in control and treatment groups (P = 0.063 and P = 
0.539, respectively).
Conclusion: Based on the findings, clofibrate may possess poten-
tials to reduce some kinds of cardiac arrhythmias. Further studies 
especially on in vivo arrhythmial models can more elucidate these 
beneficial effects of this drug.
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Introduction: The aim of this study was to investigate whether acti-
vation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) 
contributes to the development of endothelin-1 (ET-1)-induced 
endothelial dysfunction.
Patients (or Materials) and Methods: To evaluate vascular reactivity, 
isometric tension studies were performed in response to vasodilator 
agents, acetylcholine (ACh) and sodium nitroprusside (SNP), and con-
strictor agents, potassium chloride (KCl) and phenylephrine (Phe), 
in rat thoracic aorta rings incubated with or without ET-1(10-3 M, 
18 hours). To investigate mechanisms of ET-1 action, additional sets 
of experiments involving rings incubation with ET-1 alone or with 
addition of polyethylene glycol–superoxide dismutase (PEG-SOD, a 
cell permeable superoxide radical scavenger, 41 U/mL) plus apocynin 
(a NADPH oxidase inhibitor, 300 µM), and PJ34 (an inhibitor of 
polyADP-ribose polymerase, 3 × 10-6 M) for 18 hours, and both 
relaxant and constrictor responses were evaluated. Moreover, PARP-1 
and poly(ADP-ribose) (PAR, an end-product of PARP activity) expres-
sions were evaluated by Western blot and immunohistochemistry.
Results: The results of this study demonstrated that incubation of 
thoracic artery rings with ET-1 (10-3 M, 18 hours) resulted in sig-
nificant inhibition of response to ACh (an endothelium-dependent 
vasodilator) while SNP (an endothelium-independent vasodilator)-
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induced relaxation was not changed significantly. The contractile 
response to Phe significantly increased in arteries that were incubated 
with ET-1, compared with controls. In addition, PARP-1 and PARP 
expressions increased significantly in thoracic aorta rings incubated 
with ET-1. The diminished vasoreactivity in response to ACh and 
Phe as well as ET-1-related changes in expressions of PARP-1 and 
PAR were significantly improved by the concomitant incubation with 
either PEG-SOD plus apocynin, or PJ34.
Conclusion: The results of this study suggest that ET-1 causes a sig-
nificant alteration in vascular reactivity of thoracic artery, and this 
alteration seems to be via oxidative stress in thoracic artery endothe-
lium with subsequent DNA damage and activation of PARP pathway.
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Introduction: Improvement of left ventricular ejection fraction 
(LVEF) in patients with dilated cardiomyopathy (DCM) can be 
observed after a minimum of 6 months of therapy. Many factors 
contribute to the rate of improvement. We proposed to investigate the 
importance of certain clinical variables and treatment particularities 
on the prognostic of patients with DCM.
Patients (or Materials) and Methods: We included in our study 
patients selected retrospectively from the Clinical County Hospital 
database that had been admitted to the hospital between 2010 and 
2012 with the principal diagnosis of DCM, presented a reduced 
LVEF, and had a follow-up within minimum 6 months. We consid-
ered improvement an increase of > 20% the LVEF value at follow-up. 
We then separated our patients into 2 groups based on improvement 
or no improvement of LVEF. Clinical parameters were compared by 
univariable analysis. The purpose was to identify factors that were 
associated with improvement of LVEF.
Results: In the statistical model, sex, etiology of cardiomyopathy, 
disease duration, NYHA class, heart rate at rest, presence of co-
morbidities (high systolic blood pressure, diabetes), serum sodium 
levels, beta-blocker type, and adherence to treatment were signifi-
cantly associated with improvement of ejection fraction.
Conclusion: The variables observed as being associated with 
improvement of LVEF may be used to identify patients who will 
benefit from standard therapy and those who will need more aggres-
sive pharmacologic therapies or implantable devices.
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Introduction: This study was aimed to examine the effect of chronic 
taurine treatment on corpus cavernosum dysfunction in diabetic rats 
and to investigate possible underlying mechanisms.
Patients (or Materials) and Methods: Thirty male rats were ran-
domized to 3 groups of 10 each, including control, diabetic, and 
taurine-treated diabetic. Diabetes was induced in rats by streptozo-
tosin (STZ, single intraperitoneal dose of 50 mg/kg body weight). 
Taurine was administered orally for 12 weeks (1% w/v in drink-
ing water) from the day on which STZ was injected. At the end of 
the 12th week, strips of corpus cavernosum were suspended in an 
organ bath system for functional studies. Nitric oxide (NO)-mediated 
endothelium-dependent and neurogenic corpus cavernosum relaxa-
tion were evaluated by acetylcholine (ACh, 0.1 nM-100 µM) and 
electrical field stimulation (EFS, 30 V, 5 ms, 2–32 Hz), respectively. 
The expressions of endothelial nitric oxide synthase (eNOS), phos-
phorylated eNOS (p-eNOS) (Ser-1177), neuronal nitric oxide syn-
thase (nNOS), NADPH oxidase subunit gp91phox, Rho A, and Rho 
kinase in corpus cavernosum were semi-quantitatively assessed by 
immunohistochemistry.
Results: Induction of diabetes resulted in significant inhibition of 
NO-mediated endothelium-dependent and neurogenic corpus caver-
nosum relaxation. Furthermore, eNOS, p-eNOS, and nNOS expres-
sions decreased significantly in diabetic rats compared with controls, 
while gp91phox, RhoA, and Rho kinase expressions increased signifi-
cantly. The diminished relaxation response to ACh and EFS as well 
as diabetes-related changes in expressions of these proteins in corpus 
cavernosum of diabetic rats were significantly improved by taurine.
Conclusion: Chronic treatment with taurine improves NO-mediated 
relaxations of corpus cavernosum in diabetic rats, probably by inhib-
iting NADPH oxidase/Rho kinase pathways.
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Introduction: Busulfan has documented interindividual phar-
macokinetic variability. Aim of this work is to evaluate acute 
toxicity of parenteral busulfan administered with initial dose 
recommended by producer and to demonstrate the necessity of 
further intensive therapeutic drug monitoring (TDM) to target 
desired exposure.
Patients (or Materials) and Methods: After the provision of an 
informed consent for the procedure per protocol, which has been 
approved by an independent ethical committee, 46 children (male, 
27; median age, 24 months (2 mo–18 years) underwent condition-
ing with parenteral busulfan and other drugs in different combina-
tions for autologous (n = 11) or allogeneic (n = 35) HSCT. Busulfan 
was infused in 42 patients (91%) over 4 days in 16 doses 2 hour 
infusion q6 hourrs with initial dose calculated on body weight (bw; 
< 9 kg 1.0 mg/kg, 9 < 16 kg 1.2 mg/kg, 16–23 kg 1.1 mg/kg, 23 < 34 
kg 0.95 mg/kg, > 34 kg 0.8 mg/kg). In 4 patients (9%), the scheme 
was 4-hour infusion q12 hours for 4 days, starting dose 2 mg/kg bw. 
TDM was performed prospectively online. Samples were collected for 
2-3 days starting 24 hours after initial dose (immediately before, at 
the end, 2 and 4 hours after the end of infusion). Busulfan concentra-
tion was determined by high-performance liquid chromatography. 
Further doses were changed according to calculated AUC (targeted in 
myeloablative range-infusion q6 hours: 5000–7000 ng/m.h, infusion 
q12 hours: 10,000–12,000 ng/mL.h).
